References
- Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000;1:53–66.
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;2:74–108.
- Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–42.
- Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391.
- Pfreundschuh M. How I treat elderly patients with diffuse large B-cell lymphoma. Blood 2010;116:5103–5110.
- Di Renzo N, Luminari S, Montanini A, et al. Early response to a short course of induction chemotherapy overcomes the prognostic role of IPI in patients with aggressive NHL. Preliminary results of the GISL LA05 trial. Blood 2006; 108(Suppl. 1): Abstract 2434.
- Merli F, Luminari S, Tucci A, et al. R-CHOP vs R-miniCEOP in elderly patients with diffuse large B-cell lymphoma (B-DLCL) prospectively selected by a multidimensional evaluation scale: preliminary results of a randomized study performed by Intergruppo Italiano Linfomi (IIL). Blood 2007;110(Suppl. 1): Abstract 3429.
- Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958;53:457–481.
- Cox D. Regression models and life tables. J R Stat Soc B 1972;34:187–202.
- Schoenfeld D. Partial residuals for the proportional hazard regression model. Biometrika 1982;69:239–241.
- The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993;3298:987–994.
- Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. NEngl J Med 1998;339:21–26.
- Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med 2005;352:1197–1205.
- Horning SJ, Weller E, Kim K, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin’s lymphoma: Eastern Cooperative Oncology Group study 1484. J Clin Oncol 2004;22:3032–3038.
- Bonnet C, Fillet G, Mounier N, et al. CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 2007;25:787–792.
- Miller TP, Leblanc M, Spier C, et al. CHOP alone compared to CHOP plus radiotherapy for early aggressive non-Hodgkin’s lymphoma: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001;98(Suppl. 1): Abstract 724.
- Mannina D, Luminari S, Dondi A, et al. Long term outcome of patients with localized aggressive non-Hodgkin lymphoma treated with PROMECE-CYTABOM plus involved-field radiation therapy: a study by the Gruppo Italiano Studio Linfomi. Leuk Lymphoma 2010;51:422–429.
- Avilés A, Neri N, Delgado S, et al. Residual disease after chemotherapy in aggressive malignant lymphoma: the role of radiotherapy. Med Oncol 2005;22:383–387.
- Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258–2263.
- Phan J, Mazloom A, Jeffrey Medeiros L, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol 2010;28:4170–4176.